menu
    • menu
    [{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Beat AML, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine","moa":"CD200","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beat AML, LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beat AML, LLC \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Beat AML, LLC \/ Not Applicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Daunorubicin","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Not Applicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Entospletinib","moa":"Syk","graph1":"Oncology","graph2":"Phase III","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kronos Bio \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Entospletinib","moa":"Syk","graph1":"Oncology","graph2":"Phase III","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kronos Bio \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Daunorubicin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Daunorubicin

    Menu

    Daunorubicin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-...

                            Details : VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.

                            Brand Name : Vanflyta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 09, 2023

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML

                            Details : VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.

                            Brand Name : Vanflyta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 09, 2023

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area :

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VANFLYTA® First FLT3 Inhibitor Approved in Japan for Patients with Newly Diagnosed FLT3-ITD Positive AML

                            Details : Vanflyta (quizartinib) is an oral, highly potent type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.

                            Brand Name : Vanflyta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 25, 2023

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area :

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA

                            Details : Vanflyta (quizartinib) is an oral, highly potent type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.

                            Brand Name : Vanflyta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 20, 2023

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jazz Pharmaceuticals

                            Ireland arrow
                            American Pharma Summit
                            Not Confirmed

                            Jazz Pharmaceuticals

                            Ireland arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daunorubicin,Cytarabine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jazz Pharmaceuticals Secures Eight Additional Provincial Reimbursements for Vyxeos® for Treatment of Adults w...

                            Details : Vyxeos (daunorubicin and cytarabine) have synergistic effects at killing leukemia cells by inhibiting DNA polymerase activity, is indicated as a chemotherapy treatment option specifically indicated for the treatment of adults with newly diagnosed t-AML o...

                            Brand Name : Vyxeos

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 08, 2023

                            Lead Product(s) : Daunorubicin,Cytarabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myel...

                            Details : Submission based on QuANTUM-First results showing Vanflyta (quizartinib) an oral, highly potent and selective type II FLT3 inhibitor plus chemotherapy significantly improved overall survival compared to chemotherapy alone.

                            Brand Name : Vanflyta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 24, 2022

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quizartinib Marketing Authorization Application Validated by EMA for Treatment of Adult Patients with Newly Di...

                            Details : Submission based on QuANTUM-First results showing Vanflyta (quizartinib) plus chemotherapy significantly improved overall survival compared to chemotherapy alone.

                            Brand Name : Vanflyta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 23, 2022

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients wit...

                            Details : Positive results from Vanflyta (quizartinib) combined with standard induction and chemotherapy demonstrated statistically significant and meaningful improvement in OS in adult patients with newly diagnosed FLT3-ITD positive AML compared to standard chemo...

                            Brand Name : Vanflyta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 11, 2022

                            Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kronos Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entospletinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclini...

                            Details : First poster describes the analysis of mutational and gene expression signatures from bone marrow and peripheral blood samples of patients with NPM1-mutated AML, with or without co-mutation of FLT3, is a strong predictor of GS-9973 (entospletinib) anti-l...

                            Brand Name : GS-9973

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 10, 2022

                            Lead Product(s) : Entospletinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kronos Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entospletinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presen...

                            Details : GS-9973 (entospletinib) is a selective inhibitor targeting spleen tyrosine kinase (SYK), a critical node in a dysregulated transcription regulatory network within AML defined by persistent high expression of the transcription factors HOXA9 and MEIS1.

                            Brand Name : GS-9973

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 12, 2022

                            Lead Product(s) : Entospletinib,Cytarabine,Daunorubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth